Upcoming Dividend • Jul 01
Upcoming dividend of NT$1.00 per share Eligible shareholders must have bought the stock before 08 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (1.2%). Reported Earnings • May 15
First quarter 2026 earnings released: EPS: NT$0.078 (vs NT$0.19 in 1Q 2025) First quarter 2026 results: EPS: NT$0.078 (down from NT$0.19 in 1Q 2025). Revenue: NT$527.7m (down 3.7% from 1Q 2025). Net income: NT$5.27m (down 60% from 1Q 2025). Profit margin: 1.0% (down from 2.4% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. New Risk • Apr 05
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.3% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.9% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.91b market cap, or US$90.9m). Reported Earnings • Mar 17
Full year 2025 earnings released: EPS: NT$2.28 (vs NT$1.91 in FY 2024) Full year 2025 results: EPS: NT$2.28 (up from NT$1.91 in FY 2024). Revenue: NT$2.95b (up 20% from FY 2024). Net income: NT$153.0m (up 19% from FY 2024). Profit margin: 5.2% (in line with FY 2024). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Annonce • Mar 13
All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2026 All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 16, 2026. Location: 15 floor no,99, fu hsing n. rd., taipei city Taiwan Reported Earnings • Nov 18
Third quarter 2025 earnings released: EPS: NT$1.02 (vs NT$1.07 in 3Q 2024) Third quarter 2025 results: EPS: NT$1.02 (down from NT$1.07 in 3Q 2024). Revenue: NT$829.8m (up 11% from 3Q 2024). Net income: NT$68.8m (down 4.6% from 3Q 2024). Profit margin: 8.3% (down from 9.7% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 31
Second quarter 2025 earnings released: EPS: NT$0.56 (vs NT$0.12 in 2Q 2024) Second quarter 2025 results: EPS: NT$0.56 (up from NT$0.12 in 2Q 2024). Revenue: NT$739.5m (up 55% from 2Q 2024). Net income: NT$36.1m (up 353% from 2Q 2024). Profit margin: 4.9% (up from 1.7% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Aug 07
Upcoming dividend of NT$0.50 per share Eligible shareholders must have bought the stock before 14 August 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (2.8%). Reported Earnings • May 15
First quarter 2025 earnings released: EPS: NT$0.20 (vs NT$0.45 in 1Q 2024) First quarter 2025 results: EPS: NT$0.20 (down from NT$0.45 in 1Q 2024). Revenue: NT$547.9m (up 4.7% from 1Q 2024). Net income: NT$13.1m (down 54% from 1Q 2024). Profit margin: 2.4% (down from 5.4% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Annonce • May 06
All Cosmos Bio-Tech Holding Corporation to Report Q1, 2025 Results on May 13, 2025 All Cosmos Bio-Tech Holding Corporation announced that they will report Q1, 2025 results on May 13, 2025 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to NT$33.45, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 17x in the Chemicals industry in Taiwan. Total loss to shareholders of 57% over the past three years. Reported Earnings • Mar 26
Full year 2024 earnings released: EPS: NT$2.01 (vs NT$2.18 in FY 2023) Full year 2024 results: EPS: NT$2.01 (down from NT$2.18 in FY 2023). Revenue: NT$2.46b (down 13% from FY 2023). Net income: NT$128.6m (down 7.7% from FY 2023). Profit margin: 5.2% (up from 4.9% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Annonce • Mar 06
All Cosmos Bio-Tech Holding Corporation to Report Fiscal Year 2024 Results on Mar 13, 2025 All Cosmos Bio-Tech Holding Corporation announced that they will report fiscal year 2024 results on Mar 13, 2025 Reported Earnings • Nov 18
Third quarter 2024 earnings released: EPS: NT$1.13 (vs NT$1.07 in 3Q 2023) Third quarter 2024 results: EPS: NT$1.13 (up from NT$1.07 in 3Q 2023). Revenue: NT$746.3m (up 8.4% from 3Q 2023). Net income: NT$72.1m (up 5.0% from 3Q 2023). Profit margin: 9.7% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Annonce • Nov 05
All Cosmos Bio-Tech Holding Corporation to Report Q3, 2024 Results on Nov 12, 2024 All Cosmos Bio-Tech Holding Corporation announced that they will report Q3, 2024 results on Nov 12, 2024 Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to NT$52.50, the stock trades at a trailing P/E ratio of 34.8x. Average forward P/E is 20x in the Chemicals industry in Taiwan. Total returns to shareholders of 52% over the past three years. Reported Earnings • Aug 31
Second quarter 2024 earnings released: EPS: NT$0.12 (vs NT$0.61 in 2Q 2023) Second quarter 2024 results: EPS: NT$0.12 (down from NT$0.61 in 2Q 2023). Revenue: NT$478.4m (down 39% from 2Q 2023). Net income: NT$7.96m (down 80% from 2Q 2023). Profit margin: 1.7% (down from 4.9% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Annonce • Aug 20
All Cosmos Bio-Tech Holding Corporation to Report Q2, 2024 Results on Aug 27, 2024 All Cosmos Bio-Tech Holding Corporation announced that they will report Q2, 2024 results on Aug 27, 2024 Upcoming Dividend • Jul 04
Upcoming dividend of NT$1.00 per share Eligible shareholders must have bought the stock before 11 July 2024. Payment date: 01 August 2024. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Taiwanese dividend payers (4.2%). In line with average of industry peers (2.2%). Reported Earnings • May 19
First quarter 2024 earnings released: EPS: NT$0.44 (vs NT$0.63 in 1Q 2023) First quarter 2024 results: EPS: NT$0.44 (down from NT$0.63 in 1Q 2023). Revenue: NT$523.5m (down 33% from 1Q 2023). Net income: NT$28.5m (down 29% from 1Q 2023). Profit margin: 5.4% (up from 5.2% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • May 15
Dividend of NT$1.00 announced Shareholders will receive a dividend of NT$1.00. Ex-date: 11th July 2024 Payment date: 1st August 2024 Dividend yield will be 1.9%, which is lower than the industry average of 4.0%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 49% to shift the payout ratio to a potentially unsustainable range, which is more than the 15% EPS decline seen over the last 5 years. Annonce • May 05
All Cosmos Bio-Tech Holding Corporation to Report Q1, 2024 Results on May 13, 2024 All Cosmos Bio-Tech Holding Corporation announced that they will report Q1, 2024 results on May 13, 2024 New Risk • Apr 15
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.9% net profit margin). Market cap is less than US$100m (NT$3.23b market cap, or US$99.8m). Annonce • Mar 27
All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024 All Cosmos Bio-Tech Holding Corporation, Annual General Meeting, Jun 21, 2024. Reported Earnings • Mar 19
Full year 2023 earnings released: EPS: NT$2.18 (vs NT$5.75 in FY 2022) Full year 2023 results: EPS: NT$2.18 (down from NT$5.75 in FY 2022). Revenue: NT$2.83b (down 24% from FY 2022). Net income: NT$139.4m (down 62% from FY 2022). Profit margin: 4.9% (down from 9.9% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Annonce • Feb 01
All Cosmos Bio-Tech Holding Corporation Announces the Retirement of Ling Siu Hung as Chief Operating Officer All Cosmos Bio-Tech Holding Corporation announced the retirement of Ling Siu Hung as Chief Operating Officer, effective January 31, 2024. Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to NT$50.10, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 21x in the Chemicals industry in Taiwan. Total returns to shareholders of 53% over the past three years. New Risk • Nov 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 32% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.2% net profit margin). Market cap is less than US$100m (NT$2.78b market cap, or US$88.8m). Reported Earnings • Nov 14
Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$2.48 in 3Q 2022) Third quarter 2023 results: EPS: NT$1.07 (down from NT$2.48 in 3Q 2022). Revenue: NT$688.7m (down 45% from 3Q 2022). Net income: NT$68.7m (down 57% from 3Q 2022). Profit margin: 10.0% (down from 13% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. New Risk • Sep 10
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: NT$0.61 (vs NT$1.47 in 2Q 2022) Second quarter 2023 results: EPS: NT$0.61 (down from NT$1.47 in 2Q 2022). Revenue: NT$786.5m (down 14% from 2Q 2022). Net income: NT$38.9m (down 59% from 2Q 2022). Profit margin: 4.9% (down from 10% in 2Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. New Risk • Aug 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.17b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$3.17b market cap, or US$99.7m). Upcoming Dividend • Jul 03
Upcoming dividend of NT$2.50 per share at 4.1% yield Eligible shareholders must have bought the stock before 10 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 47% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (3.7%). Reported Earnings • Mar 28
Full year 2022 earnings released: EPS: NT$5.75 (vs NT$3.09 in FY 2021) Full year 2022 results: EPS: NT$5.75 (up from NT$3.09 in FY 2021). Revenue: NT$3.70b (up 69% from FY 2021). Net income: NT$368.2m (up 86% from FY 2021). Profit margin: 9.9% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to NT$66.00, the stock trades at a trailing P/E ratio of 10.5x. Average forward P/E is 16x in the Chemicals industry in Taiwan. Total returns to shareholders of 95% over the past three years. Reported Earnings • Nov 18
Third quarter 2022 earnings released: EPS: NT$2.48 (vs NT$0.76 in 3Q 2021) Third quarter 2022 results: EPS: NT$2.48 (up from NT$0.76 in 3Q 2021). Revenue: NT$1.24b (up 127% from 3Q 2021). Net income: NT$158.7m (up 225% from 3Q 2021). Profit margin: 13% (up from 8.9% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to decline by 1.1% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Taiwan are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorated over the past week After last week's 15% share price decline to NT$51.60, the stock trades at a trailing P/E ratio of 11.3x. Average forward P/E is 12x in the Chemicals industry in Taiwan. Total returns to shareholders of 36% over the past three years. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to NT$55.70, the stock trades at a trailing P/E ratio of 12.2x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total returns to shareholders of 40% over the past three years. Reported Earnings • Sep 01
Second quarter 2022 earnings released: EPS: NT$1.47 (vs NT$0.66 in 2Q 2021) Second quarter 2022 results: EPS: NT$1.47 (up from NT$0.66 in 2Q 2021). Revenue: NT$912.0m (up 61% from 2Q 2021). Net income: NT$94.3m (up 124% from 2Q 2021). Profit margin: 10% (up from 7.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Board Change • Aug 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment improved over the past week After last week's 17% share price gain to NT$60.20, the stock trades at a trailing P/E ratio of 16.1x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 23% share price gain to NT$54.40, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 17% over the past three years. Board Change • Jul 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non Independent Director Tau Lim was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Jun 16
Upcoming dividend of NT$1.50 per share Eligible shareholders must have bought the stock before 23 June 2022. Payment date: 20 July 2022. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (6.0%). Lower than average of industry peers (6.8%). Reported Earnings • May 14
First quarter 2022 earnings released: EPS: NT$1.07 (vs NT$0.42 in 1Q 2021) First quarter 2022 results: EPS: NT$1.07 (up from NT$0.42 in 1Q 2021). Revenue: NT$665.6m (up 62% from 1Q 2021). Net income: NT$68.5m (up 153% from 1Q 2021). Profit margin: 10% (up from 6.6% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorated over the past week After last week's 20% share price decline to NT$68.20, the stock trades at a trailing P/E ratio of 22x. Average forward P/E is 12x in the Chemicals industry in Taiwan. Total returns to shareholders of 44% over the past three years. Price Target Changed • Apr 27
Price target increased to NT$102 Up from NT$68.00, the current price target is provided by 1 analyst. New target price is 34% above last closing price of NT$76.40. Stock is up 97% over the past year. The company posted earnings per share of NT$3.09 last year. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 5 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Wen Lee was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improved over the past week After last week's 19% share price gain to NT$75.30, the stock trades at a trailing P/E ratio of 24.3x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total returns to shareholders of 49% over the past three years. Reported Earnings • Mar 30
Full year 2021 earnings released: EPS: NT$3.09 (vs NT$1.28 in FY 2020) Full year 2021 results: EPS: NT$3.09 (up from NT$1.28 in FY 2020). Revenue: NT$2.20b (up 34% from FY 2020). Net income: NT$198.1m (up 141% from FY 2020). Profit margin: 9.0% (up from 5.0% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 22% compared to a 2.7% decline forecast for the industry in Taiwan. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 23% share price gain to NT$64.20, the stock trades at a trailing P/E ratio of 26.8x. Average forward P/E is 11x in the Chemicals industry in Taiwan. Total returns to shareholders of 21% over the past three years. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment improved over the past week After last week's 16% share price gain to NT$48.50, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 19x in the Chemicals industry in Taiwan. Total loss to shareholders of 14% over the past three years. Reported Earnings • Nov 12
Third quarter 2021 earnings released: EPS NT$0.76 (vs NT$0.54 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$548.7m (up 15% from 3Q 2020). Net income: NT$48.9m (up 42% from 3Q 2020). Profit margin: 8.9% (up from 7.3% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment improved over the past week After last week's 16% share price gain to NT$39.35, the stock trades at a trailing P/E ratio of 18.1x. Average forward P/E is 13x in the Chemicals industry in Taiwan. Total loss to shareholders of 37% over the past three years. Reported Earnings • Aug 31
Second quarter 2021 earnings released: EPS NT$0.66 (vs NT$0.60 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: NT$565.5m (up 43% from 2Q 2020). Net income: NT$42.2m (up 9.2% from 2Q 2020). Profit margin: 7.5% (down from 9.7% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 29
Upcoming dividend of NT$1.00 per share Eligible shareholders must have bought the stock before 06 July 2021. Payment date: 30 July 2021. Trailing yield: 2.9%. Lower than top quartile of Taiwanese dividend payers (4.9%). In line with average of industry peers (2.8%). Reported Earnings • May 14
First quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.41 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$409.9m (up 91% from 1Q 2020). Net income: NT$27.1m (up NT$53.3m from 1Q 2020). Profit margin: 6.6% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance. Annonce • May 12
All Cosmos Bio-Tech Holding Corporation Announces Cash Dividend, Payable on July 30, 2021 All Cosmos Bio-Tech Holding Corporation announced Cash dividend of NTD 64,034,001 with Ex-rights (ex-dividend) record date July 12,2021, and payment date of July 30, 2021. Price Target Changed • Apr 20
Price target decreased to NT$40.00 Down from NT$98.50, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of NT$40.70. Stock is up 63% over the past year. Annonce • Jan 22
Acting for the Malaysian Subsidiary All Cosmos Bio-Tech Holding Corporation to Announce Temporary Shutdown of the Production Department A foreign outsourcing employee from West Malaysia subsidiary All Cosmos Bio-Tech Holding Corporation is confirmed with Covid-19.To avoid the spread of the epidemic,the company decides to temporarily shutdown Production Department from 21st of January to 26th of January, and conduct disinfection and comprehensive inspection during the shutdown period. Employees tested with negative result can enter into factory to resume work. Is New 90 Day High Low • Jan 07
New 90-day high: NT$39.40 The company is up 9.0% from its price of NT$36.10 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 15% over the same period. Reported Earnings • Nov 13
Third quarter 2020 earnings released: EPS NT$0.54 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$475.3m (up 4.9% from 3Q 2019). Net income: NT$34.5m (up 436% from 3Q 2019). Profit margin: 7.3% (up from 1.4% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 70% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 29
New 90-day low: NT$33.80 The company is down 4.0% from its price of NT$35.10 on 30 July 2020. The Taiwanese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.